If I recall correctly, Phil Nadeau was named best biotech analyst in the industry by his peers not long ago. My comment in #352 that the analysts on GTC’s latest CC did not have a strong working knowledge of GTC’s business was not intended to be a personal slight of Nadeau; rather, it was meant to convey the reality that no analyst can follow a large number of biotech companies and truly be up to speed on all of them.
Market Data 
Markets 
AI
